Results 71 to 80 of about 20,912 (233)

Progress in RNA‐Targeted Therapeutics for Human Diseases

MedComm, Volume 7, Issue 2, February 2026.
RNA‐targeted therapies are revolutionizing molecular medicine by transitioning from a “protein‐centric” focus to an “RNA‐regulatory network” approach. Leveraging RNA's diverse roles in gene regulation, signaling, and epigenetic modifications, advanced platforms such as ASOs, siRNA, miRNA, mRNA, aptamers, shRNA, and CRISPR/Cas systems are enabling ...
Wangzheqi Zhang, Aimin Jiang, Bin‐Kui Jia, Yuming Jin, Yinghu Chen, Zhaoyu Li, Yan Liao, Haoling Zhang, Zhiheng Lin, Xiao Fang, Linhui Wang   +10 more
wiley   +1 more source

Proteomic profiling of gamma-secretase substrates and mapping of substrate requirements. [PDF]

PLoS Biology, 2008
The presenilin/gamma-secretase complex, an unusual intramembrane aspartyl protease, plays an essential role in cellular signaling and membrane protein turnover.
Matthew L Hemming, Joshua E Elias, Steven P Gygi, Dennis J Selkoe   +3 more
doaj   +1 more source

Noninvasive imaging of amyloid‐beta and tau in rodent and nonhuman primate models

VIEW, Volume 7, Issue 1, February 2026.
Imaging of amyloid‐beta plaque and tau accumulation in rodent and nonhuman primate model of Alzheimer's disease. Created in BioRender. Ni R. 2026. https://BioRender.com/a97h5ec Abstract Neurodegenerative diseases are characterized by the aberrant accumulation of protein aggregates.
Ruiqing Ni, Axel Rominger
wiley   +1 more source

Synaptic Vesicle Glycoprotein 2A Suppresses Amyloidogenesis Beyond Its Synaptic Role: A Novel Mechanism Disrupting BACE1 Binding and Altering APP Localization

Aging Cell, Volume 25, Issue 2, February 2026.
Synaptic vesicle glycoprotein 2A, the newly identified APP‐binding protein, reduces amyloid‐β plaque deposition in Alzheimer's disease by suppressing the amyloidogenic pathway through inhibition of BACE1‐APP interaction and alteration of APP endosomal‐lysosomal localization.
Xiaoling Wang, Qian Zhang, Xiaomin Zhang, Jing Liu, Jingjing Zhang, Congcong Liu, Yuting Cui, Qiao Song, Yuli Hou, Yaqi Wang, Min Cao, Peichang Wang   +11 more
wiley   +1 more source

Activation of the γ-secretase complex and presence of γ-secretase-activating protein may contribute to Aβ42 production in sporadic inclusion-body myositis muscle fibers

Neurobiology of Disease, 2012
The muscle-fiber phenotype of sporadic inclusion-body myositis (s-IBM), the most common muscle disease associated with aging, shares several pathological abnormalities with Alzheimer disease (AD) brain, including accumulation of amyloid-β 42 (Aβ42) and ...
Anna Nogalska, Carla D'Agostino, W. King Engel, Valerie Askanas   +3 more
doaj   +1 more source

Targeted Nanodelivery of WGX50 and Curcumin via Gold Nanoparticles for Alzheimer's Therapy

Journal of Cellular and Molecular Medicine, Volume 30, Issue 3, February 2026.
ABSTRACT Alzheimer's disease (AD) is a progressive neurodegenerative disorder, posing a global health challenge. It affects millions of people, causing cognitive decline and a heavy burden on healthcare systems. Neuroinflammation is a key pathological feature of AD, often associated with the dysregulation of microRNAs such as hsa‐miR‐146a‐5p. WGX50 (N‐[
Madeeha Shahzad Lodhi, Muhammad Maisam, Muhammad Tahir Khan, Amina Bibi, Dongqing Wei, Kejie Mou   +5 more
wiley   +1 more source

Amyloid β—Cholesterol Interplay: Removal of Cholesterol From the Membranes to Catalyze Aggregation and Amyloid Pathology

Journal of Neurochemistry, Volume 170, Issue 2, February 2026.
The interplay between the cholesterol metabolism and assembly of Aβ42 (Amyloid beta‐42) peptide in pathological aggregates is considered one of the major molecular mechanisms in the development of Alzheimer's disease (AD). Our combined studies revealed that Aβ42 was capable of removing cholesterol from the membrane at physiologically relevant low ...
Rishiram Baral, Ruan van Deventer, Yuri L. Lyubchenko   +2 more
wiley   +1 more source

Identification of myo-inositol hexakisphosphate (IP6) as a β-secretase 1 (BACE1) inhibitory molecule in rice grain extract and digest

FEBS Open Bio, 2014
Alzheimer’s disease (AD) is widely considered to be caused by amyloid-β peptide (Aβ) accumulation in the brain. Aβ is excised from amyloid-β precursor protein through sequential cleavage by β-secretase 1 (BACE1) and γ-secretase.
Takako K. Abe, Masayuki Taniguchi
doaj   +1 more source

USP10 in Neurological Disorders: Mechanistic Insights and Emerging Therapeutic Strategies

Annals of the New York Academy of Sciences, Volume 1556, Issue 1, February 2026.
USP10 is a deubiquitinating enzyme that affects neurological diseases through multiple mechanisms, including the accumulation of toxic proteins, autophagy, and immune responses. In this review, we discuss the structure and characteristics of USP10 and summarize the role of USP10 in neurological disorders.
Celemuge, Hongying Sun, Jia Zhang, Yang Yang, Jian Mao, Cheliger   +5 more
wiley   +1 more source

Pathological activity of familial Alzheimer’s disease-associated mutant presenilin can be executed by six different γ-secretase complexes

Neurobiology of Disease, 2007
γ-Secretase is a protease complex, which catalyzes the final of two subsequent cleavages of the β-amyloid precursor protein (APP) to release the amyloid-β peptide (Aβ) implicated in Alzheimer’s disease (AD) pathogenesis.
Keiro Shirotani, Masanori Tomioka, Elisabeth Kremmer, Christian Haass, Harald Steiner   +4 more
doaj   +1 more source